Aug. 21, 2025 5:12 PM ETKeros Therapeutics, Inc. (KROS) StockKROSEdmund InghamInvesting Group LeaderSummaryKeros Therapeutics, Inc. faces uncertainty after discontinuing its lead asset, with current value driven mainly by a strong cash position and pipeline potential.KER-065 received FDA Orphan Drug designation for Duchenne Muscular Dystrophy, but efficacy and approval remain years away and unproven.Elritercept, now partnered with Takeda, offers milestone and royalty potential, but faces tough competition and uncertain commercial prospects.Given limited near-term catalysts and high risk, I maintain a Hold rating—Keros is interesting, but KROS stock lacks enough data for a bullish stance.Sally Anscombe/DigitalVision via Getty ImagesInvestment OverviewThe last time I covered Keros Therapeutics, Inc. (NASDAQ:KROS) in a note for Seeking Alpha, it was the worst day for the Lexington, Massachusetts-based biotech's share price in its shortIf you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth? This article was written byEdmund Ingham13.84K FollowersEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis. Learn more.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.CommentsRecommended For You